SEED Biosciences has developed DISPENCELL-TITER, an advanced impedance-based pipetting system designed to revolutionize biotherapeutic cell line development. This innovative platform enables single-cell isolation and immediate prediction of the best producers, drastically reducing the time and costs of identifying high-producing cell clones. DISPENCELL-TITER allows companies to detect “golden nugget” cells at day 0, reducing the screening timeline by up to 6 weeks and cutting costs by a factor of 10.
The platform’s value proposition includes gentle handling of cells, ensuring high cloning efficiency, and a compact, user-friendly design that fits seamlessly into existing cell line development workflows. With applications in recombinant protein production, monoclonal antibody discovery, and even cultured meat development, DISPENCELL-TITER addresses critical industrial needs. Thus, it aligns with global sustainability goals by reducing waste and energy consumption during cell culture processes.
SEED Biosciences innovation is set to become a new standard in biotherapeutics manufacturing, significantly enhancing productivity and scalability. By 2028, the company aims to generate substantial revenue and create highly skilled jobs in Switzerland and beyond.
Seed Biosciences has secured CHF 2.6 million in funding thanks to the highly competitive Swiss Accelerator program. This investment will accelerate the industrialization and market launch of DISPENCELL-TITER, positioning the company as a global leader in cell line development technology.
Evolution Europe was pivotal in securing Swiss Accelerator funding for DISPENCELL-TITER. Their expertise ensured a strong application aligned with Innosuisse’s criteria, and their ongoing support with financial reporting lets us focus on advancing our innovation.
